Daily BriefsECM

Daily Brief ECM: Weimob Placement – Share Price Momentum over the past Few Months Have Been Strong and more

In today’s briefing:

  • Weimob Placement – Share Price Momentum over the past Few Months Have Been Strong
  • Vikram Solar Pre-IPO – Has Diversified Its Sales, Although Concentration Risk Remains High
  • Hygeia Healthcare Placement (6078.HK)- The Prospect Is More Certain After the Policy Risk Is Removed

Weimob Placement – Share Price Momentum over the past Few Months Have Been Strong

By Clarence Chu

  • Weimob Inc. (2013 HK) is looking to raise about US$205m in its primary placement to fund R&D, upgrade marketing systems, and for general working capital purposes.
  • On an ADV basis, the deal is a relatively small one at just 3.6 days of the firm’s three month ADV.
  • In this note, we will run the deal through our ECM framework and talk about the recent updates.

Vikram Solar Pre-IPO – Has Diversified Its Sales, Although Concentration Risk Remains High

By Clarence Chu

  • Vikram Solar (0490158D IN) is looking to raise around US$260m in its upcoming India IPO. 
  • Vikram Solar (VS) is an integrated solar photo-voltaic (PV) modules producer and an integrated solar energy solutions provider.
  • As per CRISIL, it was one of India’s largest module manufacturers and held a 19% domestic market share, as per operational module capacity.

Hygeia Healthcare Placement (6078.HK)- The Prospect Is More Certain After the Policy Risk Is Removed

By Xinyao (Criss) Wang

  • The government has changed its tone and started to encourage social capital to run hospitals, indicating that the previous concerns about the policy risk on Hygeia has been relieved.
  • At this stage, Hygeia has more investment value, greater expansion space and higher market demand than Aier Eye Hospital. Meanwhile, the Company performs better in trans provincial expansion than Topchoice. 
  • Due to large investment/“heavy asset” model, Hygeia would continue to face capital pressure. Its expansion pace may not be as fast as expected if it hopes to control expansion quality. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars